The Economic Times

Sun Pharma places non-binding offer for US-based Organon in its boldest global bet ever

Sun Pharmaceutical Industries Ltd has submitted a non-binding offer to acquire US-based Organon for an all-cash deal, securing $10-14 billion in acquisition financing. This move marks Sun Pharma's boldest global bet, aiming to bolster its presence in women's health biopharma and biosimilars. The acquisition, if successful, would be the largest by an Indian pharmaceutical company.